The Potential Use of RNA-based Therapeutics for Breast Cancer Treatment

被引:8
|
作者
Song, Yangyang [1 ]
Ke, Xinyu [1 ,2 ]
Chen, Leilei [1 ,2 ]
机构
[1] Natl Univ Singapore, Canc Sci Inst Singapore, 14 Med Dr, Singapore 117599, Singapore
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117594, Singapore
基金
新加坡国家研究基金会;
关键词
Breast cancer; RNA therapy; antisense oligonucleotides (ASOs); aptamers; RNA interference (RNAi); clustered regularly interspaced short palindromic repeat/CRISPR-associated protein 9 (CRISPR/Cas9); MESSENGER-RNA; TAMOXIFEN RESISTANCE; CELL-PROLIFERATION; IN-VITRO; T-CELLS; GENE; ANTISENSE; THERAPY; VACCINE; DNA;
D O I
10.2174/0929867327666201117100336
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Breast cancer is one of the most lethal cancers in women worldwide, and the development of efficient treatments faces several challenges. Breast cancer is characterized by histological and functional heterogeneity in aspects such as tumorigenesis, metastasis, and drug resistance. RNA therapy has emerged as a highly attractive class of drugs for the treatment and prevention of breast cancer. It might play remarkable regulatory roles in the treatment of targeted cells by either increasing or silencing expressions of specific proteins, and such features of RNA-based drugs cause high selectivity and low risk of off-target effect in breast cancer. RNA therapy exerts anti-proliferative and pro-apoptotic effects upon cell culture systems, animal models, and in clinical trials in most studies. In this mini-review, we outline the classifications, mechanisms, advantages, and challenges of RNA therapy and highlight its application in breast cancer treatment. Additionally, we summarize the clinical trials of RNA-targeting therapies and the development of anti-tumor RNA drugs and provide future directions for RNA therapeutics in breast cancer.
引用
收藏
页码:5110 / 5136
页数:27
相关论文
共 50 条
  • [1] DNA/RNA-based formulations for treatment of breast cancer
    Xie, Zhaolu
    Zeng, Xianghui
    EXPERT OPINION ON DRUG DELIVERY, 2017, 14 (12) : 1379 - 1393
  • [2] RNA-Based Therapeutics: Current Developments in Targeted Molecular Therapy of Triple-Negative Breast Cancer
    Haque, Sakib
    Cook, Kiri
    Sahay, Gaurav
    Sun, Conroy
    PHARMACEUTICS, 2021, 13 (10)
  • [3] Theranostic Nanoparticles for RNA-Based Cancer Treatment
    Revia, Richard A.
    Stephen, Zachary R.
    Zhang, Miqin
    ACCOUNTS OF CHEMICAL RESEARCH, 2019, 52 (06) : 1496 - 1506
  • [4] Current RNA-based Therapeutics in Clinical Trials
    Zhou, Ling-Yan
    Qin, Zhou
    Zhu, Yang-Hui
    He, Zhi-Yao
    Xu, Ting
    CURRENT GENE THERAPY, 2019, 19 (03) : 172 - 196
  • [5] The potential of RNA-based therapy for kidney diseases
    Bondue, Tjessa
    van den Heuvel, Lambertus
    Levtchenko, Elena
    Brock, Roland
    PEDIATRIC NEPHROLOGY, 2023, 38 (02) : 327 - 344
  • [6] RNA-based therapeutics for colorectal cancer: Updates and future directions
    Liu, Jingwen
    Guo, Bin
    PHARMACOLOGICAL RESEARCH, 2020, 152
  • [7] RNA-based therapeutics: an overview and prospectus
    Zhu, Yiran
    Zhu, Liyuan
    Wang, Xian
    Jin, Hongchuan
    CELL DEATH & DISEASE, 2022, 13 (07)
  • [8] Emerging Progress of RNA-Based Antitumor Therapeutics
    Fu, Jiayan
    Dong, Haiyang
    Wu, Jian
    Jin, Yongfeng
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2023, 19 (10): : 3159 - 3183
  • [9] Unlocking the potential of chemically modified peptide nucleic acids for RNA-based therapeutics
    Pradeep, Sai Pallavi
    Malik, Shipra
    Slack, Frank J.
    Bahal, Raman
    RNA, 2023, 29 (04) : 434 - 445
  • [10] Challenges with the discovery of RNA-based therapeutics for flaviviruses
    Wang, Mei-Yue
    Zhao, Rong
    Wang, Yu-Lan
    Wang, De-Ping
    Cao, Ji-Min
    EXPERT OPINION ON DRUG DISCOVERY, 2023, 18 (04) : 371 - 383